<DOC>
	<DOCNO>NCT00095875</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , cisplatin , fluorouracil , carboplatin , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . It yet know regimen chemotherapy radiation therapy effective treat head neck cancer . PURPOSE : Randomized phase III trial compare effectiveness two different regimen chemotherapy radiation therapy treat patient stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Treating Patients With Stage III IV Head Neck Cancer ( Paradigm Trial )</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare 3-year survival patient previously untreated stage III IV squamous cell carcinoma head neck treat induction chemotherapy comprise docetaxel , cisplatin , fluorouracil follow radiotherapy carboplatin docetaxel v radiotherapy cisplatin . Secondary - Compare 2-year progression-free status patient treat regimen . - Compare 5-year survival patient treat regimen . - Compare 3- 5-year progression-free survival patient treat regimen . - Compare complete response rate patient treat regimen . - Compare tumor site-specific survival patient treat regimen . - Compare functional organ preservation patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . - Correlate tissue germline marker response , local/regional control , development distant metastasis patient treat regimen . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive induction chemotherapy comprise docetaxel , cisplatin , fluorouracil . Treatment repeat every 21 day 3 course . Patients achieve pathologic complete response primary site clinical complete response neck receive carboplatin weekly undergo concurrent radiotherapy daily , 5 day week , 7 week . Patients partial response primary site ( i.e. , positive biopsy ) , stable disease , radiographic evidence persistent disease neck receive docetaxel weekly 4 week undergo concurrent radiotherapy twice daily , 5 day week , 6 week . - Arm II : Patients receive cisplatin IV week 1 4 undergo concurrent radiotherapy twice daily , 5 day week , 6 week . Quality life assess baseline 3 , 12 , 24 month . Patients follow monthly 1 year , every 2 month 1 year , every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 330 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>List Histologically cytologically confirm squamous cell carcinoma head neck Stage III IV* disease One follow primary tumor site : Oral cavity No mandible invasion Oropharynx Hypopharynx Larynx The following primary tumor site exclude : Nasal cavity Paranasal cavity Nasopharynx NOTE : *No evidence distant metastasis chest xray , abdominal ultrasound , CT scan ( patient liver function test abnormality ) bone scan ( patient local symptom ) At least 1 uni bidimensionally measurable lesion PATIENT CHARACTERISTICS : Age Over 18 Performance status WHO 01 Life expectancy Not specify Hematopoietic Neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 10 g/dL Hepatic Bilirubin normal AST ALT within eligibility range Alkaline phosphatase within eligibility range Renal Creatinine clearance &gt; 60 mL/min Cardiovascular No unstable cardiac disease despite treatment No myocardial infarction within past 6 month Pulmonary No chronic obstructive pulmonary disease , define require hospitalization pneumonia respiratory decompensation within past year Obstruction cause tumor allow Neurologic No symptomatic peripheral neuropathy &gt; grade 2 No symptomatic alter hear &gt; grade 2 No history significant neurologic psychiatric disorder , include dementia seizures Other No active drug addiction , include alcohol , cocaine , intravenous drug within past 6 month No malignancy within past 5 year except adequately treat carcinoma situ cervix , basal cell squamous cell skin cancer , cancer curatively treat surgery alone No active , clinically significant , uncontrolled infection No autoimmune disease require therapy No unhealed clinically active peptic ulcer disease No hypercalcemia No serious illness medical condition No involuntary weight loss &gt; 25 % body weight within past 2 month HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery No prior organ transplantation No prior surgery cancer Biopsy allow Other More 30 day since prior participation another investigational study No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>